Market Overview:
The global prostate-specific antigen (PSA) testing market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of prostate cancer, technological advancements in PSA testing methods, and rising awareness about PSA testing. The global PSA testing market is segmented on the basis of type into CLIA method and ELISA method. The CLIA method segment is expected to dominate the market during the forecast period owing to its low cost and high accuracy as compared to other methods. On the basis of application, the market is segmented into screening, post-treatment monitoring, and other applications.
 Testing Industry Outlook.svg)
Product Definition:
A prostate-specific antigen (PSA) test measures the level of PSA in a man's blood. PSA is a protein produced by the prostate gland. The level of PSA in the blood rises when the prostate is enlarged or when cancer is present.
CLIA Method:
The CLIA method is a preferred molecular diagnostic test for the detection of prostate-specific antigen (PSA) in urine and serum. It helps detect abnormal growth of cells in the prostate gland responsible for producing PSA. The rise in prevalence of diseases such as benign prostatic hyperplasia, bladder cancer, and other related conditions are expected to boost demand over the forecast period. According to National Health Service (NHS), U.K.
ELISA Method:
ELISA (enzyme-linked immunosorbent assay) is a method used for detecting the presence of PSA in body fluids and tissues. ELISA is considered as one of the most popular methods for PSA testing owing to its ease, speed, accuracy & specificity. It also has advantages such as it can be conducted onsite without requiring central laboratory infrastructure and does not require trained personnel which are some other factors that have contributed towards its popularity over other methods.
Application Insights:
The screening segment dominated the global market in terms of revenue in 2017. The high share is attributable to the increasing incidence of prostate cancer and rising demand for early diagnosis. According to data published by the World Health Organization (WHO) in 2012, around 1 out of 6 men are expected to develop prostate cancer during their lifetime, with over 250,000 new cases being diagnosed every year globally.
In North America and Europe, PSA testing is primarily used as a screening tool for detecting prostate cancer at an early stage so that treatment can be started before symptoms become evident. In Asia Pacific region, where access to advanced healthcare facilities and treatments is relatively better than other regions; however; screening tests such as Prostate-specific Antigen (PSA) blood tests are widely used for initial detection owing to less awareness about different diagnostic options among population groups there.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of manufacturers, suppliers, and consumers has led to the dominance of this region. Moreover, rising incidence rates for prostate cancer have further fueled the regional growth. According to NCBI, as on January 1st 2018 around 629 cases were registered in U.S., with an estimated mortality rate of 15%.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to increasing awareness levels about PSA testing among men diagnosed with prostate cancer and rising healthcare expenditure by government & private sectors for early diagnosis & treatment programs across countries such as India and China. In addition, favorable government policies are also anticipated to boost regional demand during the forecast period from 2018-2030 (See Table 1).
Growth Factors:
- Increasing incidence of prostate cancer: The incidence of prostate cancer is increasing globally. This will lead to an increase in the demand for PSA testing, as it is the most common test used to screen for prostate cancer.
- Growing awareness about PSA testing: There is a growing awareness among men about the benefits of PSA testing in early detection of prostate cancer. This is likely to drive the growth of the market for PSA testing over the forecast period.
- Technological advancements in PSA tests: There have been several technological advancements in PSA tests in recent years, which has led to increased accuracy and sensitivity of these tests. This is likely to boost demand for these tests over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Prostate-specific Antigen (PSA) Testing Market Research Report
By Type
CLIA Method, ELISA Method
By Application
Screening, Post-treatment Monitoring, Other
By Companies
Abbott, Boston Scientific Corporation, Bayer AG, Siemens Healthcare, DiaSorin, Roche, Beckman Coulter, PerkinElmer, Tosoh, Ortho Clinical, Fujirebio, Mediwatch, BodiTech, Bristol-Myers Squibb Company, GE Healthcare, Endocare, Merck＆Co., Medtronic, Sanofi-Aventis SA
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
193
Number of Tables & Figures
136
Customization Available
Yes, the report can be customized as per your need.
Global Prostate-specific Antigen (PSA) Testing Market Report Segments:
The global Prostate-specific Antigen (PSA) Testing market is segmented on the basis of:
Types
CLIA Method, ELISA Method
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Screening, Post-treatment Monitoring, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott
- Boston Scientific Corporation
- Bayer AG
- Siemens Healthcare
- DiaSorin
- Roche
- Beckman Coulter
- PerkinElmer
- Tosoh
- Ortho Clinical
- Fujirebio
- Mediwatch
- BodiTech
- Bristol-Myers Squibb Company
- GE Healthcare
- Endocare
- Merck＆Co.
- Medtronic
- Sanofi-Aventis SA
 Testing Market Overview.svg)
Highlights of The Prostate-specific Antigen (PSA) Testing Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- CLIA Method
- ELISA Method
- By Application:
- Screening
- Post-treatment Monitoring
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Prostate-specific Antigen (PSA) Testing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Testing Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Prostate-specific antigen (PSA) testing is a blood test that can help doctors diagnose prostate cancer. PSA levels may increase in men with prostate cancer, and decrease in men who do not have the disease.
Some of the major companies in the prostate-specific antigen (psa) testing market are Abbott, Boston Scientific Corporation, Bayer AG, Siemens Healthcare, DiaSorin, Roche, Beckman Coulter, PerkinElmer, Tosoh, Ortho Clinical, Fujirebio, Mediwatch, BodiTech, Bristol-Myers Squibb Company, GE Healthcare, Endocare, Merck＆Co., Medtronic, Sanofi-Aventis SA.
The prostate-specific antigen (psa) testing market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Prostate-specific Antigen (PSA) Testing Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Prostate-specific Antigen (PSA) Testing Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Prostate-specific Antigen (PSA) Testing Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Prostate-specific Antigen (PSA) Testing Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Prostate-specific Antigen (PSA) Testing Market Size & Forecast, 2018-2028
4.5.1 Prostate-specific Antigen (PSA) Testing Market Size and Y-o-Y Growth
4.5.2 Prostate-specific Antigen (PSA) Testing Market Absolute $ Opportunity
Chapter 5 Global Prostate-specific Antigen (PSA) Testing Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Prostate-specific Antigen (PSA) Testing Market Size Forecast by Type
5.2.1 CLIA Method
5.2.2 ELISA Method
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Prostate-specific Antigen (PSA) Testing Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Prostate-specific Antigen (PSA) Testing Market Size Forecast by Applications
6.2.1 Screening
6.2.2 Post-treatment Monitoring
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Prostate-specific Antigen (PSA) Testing Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Prostate-specific Antigen (PSA) Testing Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Prostate-specific Antigen (PSA) Testing Analysis and Forecast
9.1 Introduction
9.2 North America Prostate-specific Antigen (PSA) Testing Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Prostate-specific Antigen (PSA) Testing Market Size Forecast by Type
9.6.1 CLIA Method
9.6.2 ELISA Method
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Prostate-specific Antigen (PSA) Testing Market Size Forecast by Applications
9.10.1 Screening
9.10.2 Post-treatment Monitoring
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Prostate-specific Antigen (PSA) Testing Analysis and Forecast
10.1 Introduction
10.2 Europe Prostate-specific Antigen (PSA) Testing Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Prostate-specific Antigen (PSA) Testing Market Size Forecast by Type
10.6.1 CLIA Method
10.6.2 ELISA Method
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Prostate-specific Antigen (PSA) Testing Market Size Forecast by Applications
10.10.1 Screening
10.10.2 Post-treatment Monitoring
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Prostate-specific Antigen (PSA) Testing Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Prostate-specific Antigen (PSA) Testing Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Prostate-specific Antigen (PSA) Testing Market Size Forecast by Type
11.6.1 CLIA Method
11.6.2 ELISA Method
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Prostate-specific Antigen (PSA) Testing Market Size Forecast by Applications
11.10.1 Screening
11.10.2 Post-treatment Monitoring
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Prostate-specific Antigen (PSA) Testing Analysis and Forecast
12.1 Introduction
12.2 Latin America Prostate-specific Antigen (PSA) Testing Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Prostate-specific Antigen (PSA) Testing Market Size Forecast by Type
12.6.1 CLIA Method
12.6.2 ELISA Method
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Prostate-specific Antigen (PSA) Testing Market Size Forecast by Applications
12.10.1 Screening
12.10.2 Post-treatment Monitoring
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Prostate-specific Antigen (PSA) Testing Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Prostate-specific Antigen (PSA) Testing Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Prostate-specific Antigen (PSA) Testing Market Size Forecast by Type
13.6.1 CLIA Method
13.6.2 ELISA Method
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Prostate-specific Antigen (PSA) Testing Market Size Forecast by Applications
13.10.1 Screening
13.10.2 Post-treatment Monitoring
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Prostate-specific Antigen (PSA) Testing Market: Competitive Dashboard
14.2 Global Prostate-specific Antigen (PSA) Testing Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbott
14.3.2 Boston Scientific Corporation
14.3.3 Bayer AG
14.3.4 Siemens Healthcare
14.3.5 DiaSorin
14.3.6 Roche
14.3.7 Beckman Coulter
14.3.8 PerkinElmer
14.3.9 Tosoh
14.3.10 Ortho Clinical
14.3.11 Fujirebio
14.3.12 Mediwatch
14.3.13 BodiTech
14.3.14 Bristol-Myers Squibb Company
14.3.15 GE Healthcare
14.3.16 Endocare
14.3.17 Merck＆Co.
14.3.18 Medtronic
14.3.19 Sanofi-Aventis SA
